These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24217789)

  • 1. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Votanopoulos KI; Randle RW; Craven B; Swett KR; Levine EA; Shen P; Stewart JH; Mirzazadeh M
    Ann Surg Oncol; 2014 Mar; 21(3):868-74. PubMed ID: 24217789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Randle RW; Doud AN; Levine EA; Clark CJ; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1634-8. PubMed ID: 25120252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Doud AN; Randle RW; Clark CJ; Levine EA; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1645-50. PubMed ID: 25120249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Ahmed S; Levine EA; Randle RW; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2014 Dec; 21(13):4226-31. PubMed ID: 25034815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors.
    Votanopoulos KI; Swords DS; Swett KR; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2013 Nov; 20(12):3899-904. PubMed ID: 23800899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.
    Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality.
    Votanopoulos KI; Newman NA; Russell G; Ihemelandu C; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2013 Oct; 20(11):3497-503. PubMed ID: 23780382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study.
    Leapman MS; Jibara G; Tabrizian P; Franssen B; Yang MJ; Romanoff A; Hall SJ; Palese M; Sarpel U; Hiotis S; Labow D
    Ann Surg Oncol; 2014 Apr; 21(4):1153-8. PubMed ID: 24322531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Lyon TD; Turner Ii RM; Nikonow TN; Wang L; Uy J; Ramalingam L; Holtzman MP; Pingpank JF; Bartlett DL; Davies BJ
    J Surg Oncol; 2016 Feb; 113(2):218-22. PubMed ID: 26775909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.